Adjunctive efgartigimod with intravenous methylprednisolone (IVMP) led to greater EDSS improvement and rapid IgG reduction in patients with acute NMOSD and MOGAD.
Intensive dosing (20 mg/kg × 2) produced faster neurological recovery and greater antibody titer reductions.
At EAN 2025, new data highlighted the potential of efgartigimod, a neonatal Fc receptor (FcRn) inhibitor, as an add-on to intravenous methylprednisolone (IVMP) for patients experiencing acute attacks of Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)—two rare but debilitating autoimmune demyelinating conditions driven b...
